Use of mavoglurant in the reduction of cocaine use or in preventing relapse into cocaine use
Inventors
Dolmetsch, Ricardo Carl Elciario • Gasparini, Fabrizio • Gomez-Mancilla, Baltazar • Johns, Donald
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-11878001-B2
Publication Date
2024-01-23
Expiration Date
Abstract
The invention relates to the use of mavoglurant, or a pharmaceutically acceptable salt thereof: in the reduction of cocaine use by a cocaine use disorder patient; in preventing relapse into cocaine use by a cocaine use disorder patient; in the promotion of cocaine abstinence by a cocaine use disorder patient; in in the treatment of the symptoms of depression or anxiety associated with cocaine use disorder.
Core Innovation
The invention relates to therapeutic use of mavoglurant, an mGluR5 antagonist, for a cocaine use disorder patient. It provides a method for reduction of cocaine use by administering mavoglurant, or a pharmaceutically acceptable salt thereof, wherein the amount and/or frequency of cocaine use by the cocaine use disorder patient is reduced.
The method further encompasses reducing cocaine use outcomes including cocaine abstinence and preventing relapse in the cocaine use disorder setting. It also includes treating depression and/or anxiety symptoms associated with cocaine use disorder.
The disclosure provides dosing and administration embodiments for mavoglurant, including an amount of 200 mg/b.i.d. It further includes immediate-release and modified-release embodiments, combination with contingency management-based therapy, concomitant administration with methadone or buprenorphine, and patient selection by genetic variation associated with cocaine use disorder.
Claims Coverage
1 independent claim is identified. It includes an administration-based method with mavoglurant (or a pharmaceutically acceptable salt) to reduce cocaine use in a cocaine use disorder patient, including a specific 200 mg/b.i.d. dosage/frequency; additional inventive features are captured in dependent claims.
Mavoglurant administration to reduce cocaine use
Administering to a cocaine use disorder patient an effective amount of mavoglurant, or a pharmaceutically acceptable salt thereof, wherein the amount and/or frequency of cocaine use by the cocaine use disorder patient is reduced.
200 mg/b.i.d. mavoglurant dose/frequency
Administering mavoglurant, or a pharmaceutically acceptable salt thereof, in an amount of 200 mg/b.i.d.
Immediate-release or modified-release form
Administering mavoglurant (or a pharmaceutically acceptable salt) in either an immediate-release form or a modified-release form.
Combination with contingency management-based therapy
Combining administration of mavoglurant (or a pharmaceutically acceptable salt) with contingency management-based therapy.
Concomitant administration with methadone or buprenorphine
Concomitantly administering mavoglurant (or a pharmaceutically acceptable salt) with methadone or buprenorphine.
Cocaine use disorder scope by cocaine administration routes/formulations
Defining that the cocaine use disorder includes cocaine administration by inhalation (smoking), intravenous injection, nasal insufflation (snorting), or oral cocaine formulations.
Patient selection by genetic variation associated with cocaine use disorder
Applying the method to a patient who has a genetic variation associated with cocaine use disorder.
Across the identified independent and dependent claim coverage, the core inventive theme is administering mavoglurant (or a pharmaceutically acceptable salt) at an effective amount including 200 mg/b.i.d. to reduce cocaine use in cocaine use disorder, optionally with specified release forms, adjunct contingency management, concomitant methadone or buprenorphine, defined cocaine administration routes/formulations, and patient selection based on genetic variation.
Stated Advantages
Reduction of the amount and/or frequency of cocaine use by a cocaine use disorder patient.
Promotion of cocaine abstinence and prevention of cocaine relapse.
Treatment of depression and/or anxiety symptoms associated with cocaine use disorder.
Documented Applications
Therapeutic treatment of cocaine use disorder using mavoglurant (mGluR5 antagonist) to reduce cocaine use, prevent relapse, and promote abstinence, including treatment of depression and anxiety symptoms associated with cocaine use disorder.
Use in combination contexts described for cocaine use disorder therapy, including contingency management-based therapy and concomitant administration with methadone or buprenorphine.
Use with specified cocaine administration routes/formulations within a cocaine use disorder population (inhalation/smoking, intravenous injection, nasal insufflation/snorting, and oral cocaine formulations).
Use in patient subpopulations having a genetic variation associated with cocaine use disorder.
Interested in licensing this patent?